Kiora Pharmaceuticals, Inc. (KPRX)
KPRX Stock Price Chart
Explore Kiora Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze KPRX price movements and trends.
KPRX Company Profile
Discover essential business fundamentals and corporate details for Kiora Pharmaceuticals, Inc. (KPRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
13 Feb 2015
Employees
12.00
Website
https://www.kiorapharma.comCEO
Brian M. Strem
Description
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
KPRX Financial Timeline
Browse a chronological timeline of Kiora Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 7 May 2026
Upcoming earnings on 14 Nov 2025
EPS estimate is -$0.72.
Earnings released on 8 Aug 2025
EPS came in at -$0.54 surpassing the estimated -$0.58 by +6.90%.
Earnings released on 9 May 2025
EPS came in at -$0.52 surpassing the estimated -$0.77 by +32.47%.
Earnings released on 25 Mar 2025
EPS came in at -$1.04 falling short of the estimated -$0.64 by -62.50%.
Earnings released on 8 Nov 2024
EPS came in at -$0.81 surpassing the estimated -$0.90 by +10.00%.
Earnings released on 9 Aug 2024
EPS came in at -$0.53 surpassing the estimated -$0.95 by +44.21%, while revenue for the quarter reached $20.00K .
Stock split effective on 11 Jun 2024
Shares were split 1 : 9 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 May 2024
EPS came in at $3.42 falling short of the estimated $5.58 by -38.71%, while revenue for the quarter reached $16.00M , meeting expectations.
Earnings released on 28 Mar 2024
EPS came in at -$0.47 falling short of the estimated -$0.42 by -11.90%, while revenue for the quarter reached $283.87K .
Earnings released on 9 Nov 2023
EPS came in at -$8.01 falling short of the estimated -$2.70 by -196.67%.
Earnings released on 8 Aug 2023
EPS came in at -$7.11 falling short of the estimated -$4.59 by -54.90%.
Earnings released on 9 May 2023
EPS came in at -$1.00 surpassing the estimated -$1.68 by +40.48%.
Earnings released on 23 Mar 2023
EPS came in at -$1.76 surpassing the estimated -$2.46 by +28.46%.
Earnings released on 9 Nov 2022
EPS came in at -$39.15 falling short of the estimated -$3.83 by -922.19%.
Stock split effective on 27 Sept 2022
Shares were split 1 : 40 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 Aug 2022
EPS came in at -$64.81 surpassing the estimated -$72.01 by +10.00%.
Earnings released on 8 Jul 2022
EPS came in at -$97.21 falling short of the estimated -$9.20 by -956.63%.
Earnings released on 15 Apr 2022
EPS came in at -$280.83 .
Earnings released on 15 Nov 2021
EPS came in at -$104.41 surpassing the estimated -$122.41 by +14.70%.
Earnings released on 12 Aug 2021
EPS came in at -$14.00 surpassing the estimated -$16.67 by +16.02%.
Earnings released on 12 May 2021
EPS came in at -$14.80 surpassing the estimated -$15.40 by +3.90%.
Earnings released on 25 Mar 2021
EPS came in at -$20.80 falling short of the estimated -$17.60 by -18.18%, while revenue for the quarter reached $12.06K .
Earnings released on 9 Nov 2020
EPS came in at -$17.60 falling short of the estimated -$16.80 by -4.76%.
KPRX Stock Performance
Access detailed KPRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.